Orient Pharma Co., Ltd. (4166.TWO)
Taipei Exchange · TWD · Healthcare · Drug Manufacturers - Specialty & Generic
NT$23.65 (-0.21%) as of
Key statistics
- Market cap
- 5.75B
- P/E (TTM)
- 23.89
- EPS (TTM)
- 0.99
- Dividend yield
- 0.00%
- 52-week range
- 22.40 – 29.60
- Beta
- 0.04
- Revenue (TTM)
- 1.52B
- Profit margin
- 15.51%
- Volume
- 56.22k
About Orient Pharma Co., Ltd.
Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.